Eman Ayman Nada

Eman Ayman Nada

Auto-generated profile, based on publicly available information

Eman Ayman Nada

Faculty of Pharmacy, Tanta University, Gharbia, Egypt

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2024 in BMC Public Health
Verified
Journal Article
Open access
PDF file
HAHossam Tharwat Ali
Hossam Tharwat Ali
MBMostafa Barakat
Mostafa Barakat
AAAhmed Reda Abdelhalim
Ahmed Reda Abdelhalim
IAIbrahim Noureddin Al-Kurd
Ibrahim Noureddin Al-Kurd
MMMuhammad Kamal-Eldeen Muhammad
Muhammad Kamal-Eldeen Muhammad
AHAbdelrahman Hendawy
Abdelrahman Hendawy
Background: Self-medication (SM) is a rising public health issue, especially in developing countries. It can be associated with various problems such as the delayed seeking of medical advice, drug interactions, and serious events such as antimicrobial drug resistance. We aimed to evaluate the Egyptian general population’s knowledge, attitudes, and practices of SM. Methods: We employed a cross-sectional design between February 7th and March 8th, 2023 using a self-administered questionnaire available in Arabic. The questionnaire was developed based on previous studies and included four domains: sociodemographic data, knowledge, attitude, and practice of SM. We utilized both online (Google Forms) and paper surveys, utilizing convenience and snowball sampling methods. Data were analyzed using R Statistical Software (v4.1.3; R Core Team 2022). Results: 1630 Egyptian individuals (838 females and 792 males) from the seven provinces were enrolled, with a median age of 25 years (IQR: 22–40). Around 55.97% and 48.28% of the participants had good knowledge and favorable attitudes regarding SM respectively, while 62.8% had practiced SM in the previous three months. The most frequently used medications were painkillers (60.74%) followed by antibiotics (32.13%) and antipyretics (28.61%). The pharmacist’s recommendation was the source of SM for 53.61% while 31.53% used old medications at home. Most participants (59.08%) practiced SM because they thought they had simple or minor symptoms. The multivariate regression analysis revealed that females had significantly higher knowledge of SM than males (aOR: 2.10; 95%CI: 1.64—2.71; p-value < 0.001), with no significant differences in practice (aOR: 1.24; 95%CI: 0.99 – 1.56; p-value = 0.065). Individuals working or studying in the medical field were significantly more knowledgeable about SM (aOR: 4.30; 95%CI: 3.27–5.69; p-value < 0.001) and more likely to practice SM (aOR: 1.65; 95%CI: 1.26–2.17; p-value < 0.001). The odds of SM decreased with favorable attitudes (aOR: 0.44; 95%CI: 0.36–0.55; p-value < 0.001) while surprisingly, knowledge level was not significantly contributing to SM practice (aOR: 1.15; 95%CI: 0.90–1.48; p-value = 0.268). Conclusions: SM is prevalent in Egypt, highlighting the importance of raising awareness and encouraging physician consultation as a priority. Governments, healthcare organizations, and educational institutions need to collaborate to provide the necessary support and resources.

5 August 2025 in Environmental Nanotechnology, Monitoring & Management
Verified
Journal Article
Open access
ENEman Ayman Nada
Eman Ayman Nada
MKMallak Eyad Abu Kaddorah
Mallak Eyad Abu Kaddorah
MJMazen El Jamal
Mazen El Jamal
AHAmal Hamad
Amal Hamad
FMFotouh R. Mansour
Fotouh R. Mansour

15 November 2025 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
ENEman Ayman Nada
Eman Ayman Nada
MEMohamed Abdelhalim Elfagieh
Mohamed Abdelhalim Elfagieh
FAFares Abdelsalam
Fares Abdelsalam
AEAsmaa Ahmed Elrashedy
Asmaa Ahmed Elrashedy
FIFatima Abdulmoain Idres
Fatima Abdulmoain Idres
BHBelal mohamed Mohamed Hamed
Belal mohamed Mohamed Hamed
Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by increased red blood cell production, with high risk of venous and arterial thrombosis. Mutations in the JAK2 gene, particularly JAK2 V617F, play a central role in its pathogenesis. Ropeginterferon alfa-2b is a novel long-acting interferon showing promise in managing PV through hematologic and molecular control. This study aimed to evaluate the efficacy and safety of Ropeginterferon alfa-2b in patients with PV based on a systematic review and meta-analysis of available clinical trials. A systematic search was conducted across PubMed, Cochrane Library, Web of Science, Google Scholar, and Scopus on May 8, 2025. Randomized controlled trials (RCTs) assessing Ropeginterferon alfa-2b in PV were included. The PRISMA guidelines were followed, and the protocol was registered in PROSPERO (CRD420251051466). Quality assessment was performed using RoB 2.0 and ROBINS-I tools. A random-effects model was applied using R software. Eight studies involving 761 patients were included and only six studies included in single arm meta-analysis with 328 patients. The pooled proportion of complete hematological response at 12 months was 0.63 (95% CI [0.51–0.73]), with high heterogeneity. Reductions in JAK2 V617F allele burden were significant (MD: 26.57, 95% CI [13.49–39.65]). Molecular response was achieved in 25% (95% CI [0.04–0.70]) of patients. The most common adverse events were elevated liver enzymes (AST: 0.28; ALT: 0.32), influenza-like illness (0.11), and anemia (0.09), with unresolved heterogeneity in all outcomes. Ropeginterferon alfa-2b shows promising efficacy in achieving hematological and molecular responses in patients with PV. However, notable heterogeneity and safety concerns, particularly liver-related adverse effects, warrant further investigation in large-scale trials. Graphical Abstract

12 November 2024 in Cureus
Verified
Journal Article
Open access
AFAya M Fayoud
Aya M Fayoud
MDMoaz Yasser Darwish
Moaz Yasser Darwish
ENEman Ayman Nada
Eman Ayman Nada
AHAbdallah A Helal
Abdallah A Helal
NMNada Shaaban Mohamed
Nada Shaaban Mohamed
MAMohamed Abd-ElGawad
Mohamed Abd-ElGawad
Folate receptor alpha (FRα) has emerged as a promising target in the treatment of ovarian cancer, with farletuzumab, a humanized monoclonal antibody targeting FRα, showing potential in clinical settings. This systematic review and single-arm meta-analysis aimed to evaluate the efficacy and safety of farletuzumab in patients with solid tumors, particularly ovarian cancer. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we conducted a thorough search across PubMed, the Web of Science, Scopus, and the Cochrane Central Register of Controlled Trials (CENTRAL) for clinical trials assessing farletuzumab in solid tumors. Data were extracted on study characteristics, patient demographics, treatment regimens, and efficacy outcomes including progression-free survival (PFS), overall survival (OS), response rates, and adverse events (AEs). The pooled analyses were performed using the Open Meta-Analyst software.

22 July 2025 in Research Square
Verified
Preprint
Open access
PDF file
MCMawadda Chukr
Mawadda Chukr
AMAhmed O. Mohamady
Ahmed O. Mohamady
FAFatima Abdallh
Fatima Abdallh
DFDoha Ahmed Farrag
Doha Ahmed Farrag
ENEman Ayman Nada
Eman Ayman Nada
MEMahmoud M. Elsayed
Mahmoud M. Elsayed
Blood donation is the best source of blood in emergencies and improves others' lives. Globally, 118.54 million blood donations occur annually, with 31.5 donations per 1,000 people in high-income countries compared to 16.4 in upper-middle-income and 5 in low-income countries. The WHO (world Health Organization) insists that countries focus on young people to achieve 100% non-remunerated voluntary blood donation (VBD). Therefore, university students are good candidates for blood donation. This review provides a better understanding of the current status of blood donation among medical students. This review systematically searched international databases (PubMed, Scopus, EMBASE, Web of Science, and Google Scholar) with relevant English studies published in English from 2000 to April 2024. study characteristics (study ID, location, study design, sampling techniques, and university), main outcome measures, and findings were extracted.We included 39 cross-sectional Knowledge, Attitude, and Practice (KAP) studies across nine countries involving 13,895 medical students. Most studies were conducted in India. all studies used different self-administrated tools to collect data. Most of the studies had fair to good quality. Positive attitudes varied widely (42%-92.6%), with the highest rates among Indian students and the lowest among Pakistani students. Donation rates ranged from 1–74%, with Nigerian students demonstrating the highest rates. This review, which analyzed 39 cross-sectional KAP studies from nine countries involving 13,895 medical students, found that most students exhibited moderate levels of knowledge, attitudes, and practices regarding blood donation. To bridge this gap, policymakers must prioritize VBD awareness campaigns, and institutions should facilitate donation opportunities and incentivize participation among medical students.

17 December 2024 in Discover Medicine
Verified
Journal Article
Open access
PDF file
ENEman Ayman Nada
Eman Ayman Nada
AHAbdallah A. Helal
Abdallah A. Helal
MKMallak Eyad Abu Kaddorah
Mallak Eyad Abu Kaddorah
MHMohamed Marey Hesn
Mohamed Marey Hesn
SHSuha Younis Hasan
Suha Younis Hasan
MAMohamed Abd-Elgawad
Mohamed Abd-Elgawad
Hyperhidrosis affects approximately 4.8% of the US population, impairing quality of life with excessive sweating. Glycopyrronium tosylate (GT), a topical anticholinergic, treats primary axillary hyperhidrosis in adults and pediatric patients. Despite its use, comprehensive evaluation of GT’s long-term safety and efficacy has been lacking. This systematic review and meta-analysis aimed to assess GT’s effectiveness and safety profiles. Following Cochrane and PRISMA guidelines, we conducted a thorough search of electronic databases for clinical trials on GT. Studies underwent quality assessment and data extraction based on predefined criteria. Primary outcomes included changes in the Dermatology Life Quality Index (DLQI), Hyperhidrosis Disease Severity Scale (HDSS), and Axillary Sweating Daily Diary (ASDD) or its change score (ASDD-C). Secondary outcomes evaluated safety concerns like mydriasis, dry mouth, urinary hesitation, and treatment-emergent adverse events. Our analysis, integrating data from three randomized controlled trials, highlights GT’s efficacy in improving quality of life and reducing sweating severity. Although minor adverse effects were reported, no significant increase in serious adverse events was observed. These findings suggest GT as a promising treatment for primary axillary hyperhidrosis, with benefits outweighing minimal side effects.